Moreover, the metabolic programs of TRM, which are skewed toward the sterol regulatory element-binding protein 2 (SREBP2)-dependent pathway, enhance tumor immunity, providing insights into potential therapeutic strategies that leverage the unique metabolic features of TRM. This evidence concerns the gene SREBF2 and neoplasm.